Successful management of a severe factor X deficiency patient with amyloidosis undergoing renal biopsy
Medicine: Case Reports and Study Protocols · 2020
DOI: 10.1097/md9.0000000000000025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicine: Case Reports and Study Protocols, 2020. Verfasst von Wei-Wei Yang und 4 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Gefördert von: National Science and Technology Major Projects for major new drugs innovation and development.
Abstract (Originalsprache)
Introduction
Systemic amyloidosis is a disease with a high risk of bleeding. The mechanism of bleeding is complex and involves multiple factors including amyloid-relating coagulopathy, platelet dysfunction and abnormal structural changes of arterioles. Among these, acquired coagulation factor X deficiency is the most common coagulopathy. Fatal bleeding may be associated with severe factor X deficiency particularly in the perioperative setting following invasive procedures. For the diagnosis of systemic amyloidosis, an invasive tissue biopsy is indispensable, and this procedure also requires close monitoring to prevent bleeding complications associated with factor X deficiency. Patient concerns: A 38-year-old Chinese man who developed nephrotic syndrome with both obviously prolonged prothrombin and activated partial thromboplastin time was admitted for further investigation. He also complained mild gingival hamorrhage intermittently for nearly 1 year. Diagnosis: The patient was diagnosed with a severe deficiency of coagulation factor X with factor X levels at 12.9%. The serum free lambda light chain was slightly elevated. A diagnosis of systemic amyloidosis was suspected. But no myocardial hypertrophy was observed. There was neither hepatomegaly nor splenomegaly. No signs of amyloidosis and plasma cells abnormality were found by routine analysis of bone marrow and abdominal fat pad biopsy samples.
Interventions
After administration of low-dose prothrombin complex concentrates which lead rise to 27.4% in factor X level, the patient underwent kidney biopsy successfully without the occurrence of major bleeding and thrombotic events. The final pathological diagnosis was renal lambda light chain amyloidosis. Outcomes: No gross hemoturia, perirenal hematoma, and a thrombotic event occurred during his hospital stay after the kidney biopsy. For further management, the patient has been advised for autologous stem cell transplantation.
Conclusion
This case report presents a rare occurrence of severe factor X deficiency in a patient diagnosed with amyloidosis. Overall coagulation state assessment before invasive procedure is helpful for bleeding-risk stratification and hemostatic-dose formulation. Proper dosage of prothrombin complex concentrates can be safe and effective in preventing factor X-related bleeding complications.
Förderung
- National Science and Technology Major Projects for major new drugs innovation and development
Zitieren
APA
Yang, W., Ma, T., Yu, X., Wang, W., & Su, T. (2020). Successful management of a severe factor X deficiency patient with amyloidosis undergoing renal biopsy. Medicine: Case Reports and Study Protocols. https://doi.org/10.1097/md9.0000000000000025
Vancouver
Yang W, Ma T, Yu X, Wang W, Su T. Successful management of a severe factor X deficiency patient with amyloidosis undergoing renal biopsy. Medicine: Case Reports and Study Protocols. 2020. doi:10.1097/md9.0000000000000025
BibTeX
@article{Yang2020,
author = {Yang, Wei-Wei and Ma, Tian-Tian and Yu, Xiao-Juan and Wang, Wen-Sheng and Su, Tao},
title = {Successful management of a severe factor X deficiency patient with amyloidosis undergoing renal biopsy},
journal = {Medicine: Case Reports and Study Protocols},
year = {2020},
doi = {10.1097/md9.0000000000000025}
}
EUVIMED